Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

NCT01050218 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

237

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Diabetic Neuropathy, Painful

Interventions

DRUG: Desvenlafaxine Succinate Sustained-Release (DVS SR)

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer